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Abstract 
Acute generalized exanthematous pustulosis (AGEP) is a dramatic generalized pustular rash 
of severe onset, which is considered a serious cutaneous adverse reaction to drugs. However, 
even though the clinical features are impressive and are often accompanied by systemic in-
flammation, it can be controlled quickly and safely by topical steroids subsequent to inter-
ruption of the offending drug. Here, we describe the management of a case and the evolu-
tion of the pustular rash. An elderly woman consulted with a generalized crop of 2–3 mm, 
nonfollicular pustules on erythematous background. In the 4 preceding weeks, she had been 
using amoxicillin/clavulanic acid for a bacterial implant infection and rivaroxaban. The clinical 
EuroSCAR criteria including the histology confirmed AGEP. Her medication was stopped and 
topical clobetasol propionate was used. Within 24 h, the development of new pustules 
ceased and the patient was discharged after 7 days of hospitalization with only a faint, dif-
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fuse erythema and focal desquamation remaining. This and many other cases in the literature 
suggest that topical steroids should be considered as a first-line treatment option, especially 
as systemic steroids themselves can sometimes induce generalized pustulosis. 
 © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
A 64-year-old Swiss pensioner presented to our hospital with a pustular rash and signs 
of systemic inflammation. The C-reactive protein was 62 mg/L and the differential blood 
count revealed leukocytosis (15.39 G/L) and neutrophilia (10.39 G/L). Five days before, she 
had first noticed abrupt onset of sheets composed of small pustules on her stomach, subse-
quently spreading to affect the neck and the palms. The day before admission, lakes of pus-
tules and papules formed on the whole body surface except the face and scalp. The trunk 
was covered with coarse scales on dark red erythema. Nikolski signs I and II were negative. 
There was no sign of mucous skin involvement. Furthermore, the patient suffered from se-
vere pruritus in the affected areas. In the 4 weeks preceding the admission, she had been 
treated with amoxicillin/clavulanic acid for a knee prosthesis infection caused by beta-
hemolytic streptococci (groups B and G), as well as with the anticoagulant rivaroxaban. A 
biopsy confirmed neutrophil infiltrates in the upper layers of the epidermis, as well as peri-
vascular and interstitial neutrophil- and eosinophil-rich infiltrates mixed with lymphocytes 
and plasma cells [1, 2]. Microbiology swabs revealed neither bacteria nor fungi.  
According to the EuroSCAR criteria [3, 4] (Table 1), the diagnosis of an acute generalized 
exanthematous pustulosis (AGEP) was made. Thus, the suspected offending drugs amoxicil-
lin/clavulanic acid and rivaroxaban were replaced with clindamycin and fractionated hepa-
rin. Topical clobetasol propionate 0.05% ointment was generously applied to all affected 
areas once daily and cold cream with 5% polidocanol, a local anesthetic, was given for the 
pruritus. Development of new pustules ceased within 24 h (Fig. 1) and pustules shed within 
72 h. The patient was discharged in good general condition after 7 days of hospitalization 
with only a faint, diffuse erythema with focal desquamation remaining (Fig. 1). Patch testing 
for the potential offending drugs was scheduled several months later. 
Discussion 
In over 90% of cases, AGEP is caused by medications. The patient has received both 
amoxicillin/clavulanic acid and rivaroxaban during the last 4 weeks before development of 
the disease. Amoxicillin has been reported to cause AGEP in multiple cases. It is also atypical 
that the drugs had started to be administered 4 weeks before the onset of disease. The in-
creased C-reactive protein is an indicator of inflammation. It is widely accepted that in a 
minority of cases also infections can cause AGEP. Our patient was suffering from an infected 
knee prosthesis, which was the target of the antibiotic treatment. Strikingly, AGEP rarely 
manifests several weeks after the culprit drugs have been initially administered. Further-
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more, rivaroxaban has not been reported to induce an AGEP. Unfortunately, the patient did 
not return to our clinic for further diagnostic procedures. 
Currently, there is no specific treatment against AGEP. The foremost intervention lead-
ing to clearing of AGEP-related pustules is the interruption of the offending drug. During the 
pustular phase, a local antiseptic treatment and moist dressings are useful, as well as topical 
corticosteroids. The latter are also effective against severe pruritus [5, 6]. Application of 
steroids more than once per day does not increase efficacy, but the onset of the therapeutic 
effect may be faster [7]. In patients with systemic inflammation such as our case, systemic 
steroids themselves can induce pustulosis [8], which may be considered a reason to avoid 
them if possible. All reports on AGEP favor the application of parental steroids. It remains 
uncertain, if a systemic application is necessary. Our patient recovered in a very short time 
by stopping the medication intake and by the use of highly potent topical corticosteroids 
once daily. 
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Fig. 1. Flank of the patient at admission (a) and after 24 h (b), 48 h (c), 72 h (d), 4 days (e), and 5 days (f). 
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Table 1. EuroSCAR criteria: diagnostic score for validation of AGEP 
  
  
Pustules  
Typical 0+2 
Compatible with the disease 0+1 
Insufficient 0+0 
    Erythema  
Typical 0+2 
Compatible with the disease 0+1 
Insufficient 0+0 
    Distribution  
Typical 0+2 
Compatible with the disease 0+1 
Insufficient 0+0 
    Postpustular desquamation  
Yes 0+1 
No 0+0 
    Course  
Mucous membrane involvement  
Yes 0−2 
No 0+0 
Acute onset  
Yes 0+0 
No 0−2 
Resolution  
Yes 0+0 
No 0−4 
Fever ≥38°C  
Yes 0+1 
No 0+0 
Polymorphonuclear cells ≥7/µL  
Yes 0+1 
No 0+0 
Histology  
Other disease −10 
Not representative 0+0 
Exocytosis of polymorphonuclear cells 0+1 
Subcorneal and/or intraepidermal nonspongi- 
00form pustules or 
 
0 
NOS pustules with papillary edema or subcorneal  
and/or intraepidermal spongiform pustules or  
NOS pustules without papillary edema                                +2     
Spongiform subcorneal and/or intraepidermal  
00pustules with papillary edema 
 
0+3 
  
  
≤0: excluded; 1–4: possible; 5–7: probable; 8–12: definite. NOS, not 
otherwise specified. 
 
   
